Fisher Asset Management LLC Has $30.12 Million Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

Fisher Asset Management LLC trimmed its holdings in Blueprint Medicines Co. (NASDAQ:BPMC) by 14.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 326,564 shares of the biotechnology company’s stock after selling 55,349 shares during the period. Fisher Asset Management LLC owned 0.54% of Blueprint Medicines worth $30,122,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. boosted its position in Blueprint Medicines by 0.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 37,414 shares of the biotechnology company’s stock worth $3,451,000 after purchasing an additional 145 shares during the period. Van ECK Associates Corp grew its stake in Blueprint Medicines by 28.4% in the 4th quarter. Van ECK Associates Corp now owns 872 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 193 shares during the last quarter. Diversified Trust Co raised its holdings in Blueprint Medicines by 2.9% in the 3rd quarter. Diversified Trust Co now owns 11,219 shares of the biotechnology company’s stock valued at $563,000 after acquiring an additional 318 shares during the period. PNC Financial Services Group Inc. lifted its position in Blueprint Medicines by 63.4% during the third quarter. PNC Financial Services Group Inc. now owns 848 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 329 shares during the last quarter. Finally, Los Angeles Capital Management LLC boosted its holdings in shares of Blueprint Medicines by 2.5% during the third quarter. Los Angeles Capital Management LLC now owns 14,493 shares of the biotechnology company’s stock worth $728,000 after acquiring an additional 355 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. HC Wainwright increased their target price on Blueprint Medicines from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Friday. JMP Securities increased their price objective on Blueprint Medicines from $114.00 to $125.00 and gave the stock a “market outperform” rating in a research report on Friday. Stifel Nicolaus boosted their target price on shares of Blueprint Medicines from $120.00 to $130.00 and gave the company a “buy” rating in a research report on Friday, April 26th. Wedbush reaffirmed an “outperform” rating and set a $110.00 price target on shares of Blueprint Medicines in a research report on Friday, April 26th. Finally, StockNews.com raised shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a report on Friday. Three research analysts have rated the stock with a sell rating, four have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $94.87.

Insider Activity

In related news, EVP Tracey L. Mccain sold 5,194 shares of the company’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $90.69, for a total transaction of $471,043.86. Following the completion of the transaction, the executive vice president now directly owns 60,498 shares in the company, valued at approximately $5,486,563.62. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, Director Jeffrey W. Albers sold 25,073 shares of the business’s stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $87.28, for a total transaction of $2,188,371.44. Following the sale, the director now directly owns 176,050 shares in the company, valued at $15,365,644. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Tracey L. Mccain sold 5,194 shares of Blueprint Medicines stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $90.69, for a total transaction of $471,043.86. Following the sale, the executive vice president now owns 60,498 shares in the company, valued at $5,486,563.62. The disclosure for this sale can be found here. In the last three months, insiders have sold 92,289 shares of company stock worth $8,314,163. Corporate insiders own 3.88% of the company’s stock.

Blueprint Medicines Stock Up 0.2 %

NASDAQ BPMC opened at $107.19 on Friday. The business has a fifty day moving average price of $91.77 and a two-hundred day moving average price of $80.52. The stock has a market capitalization of $6.56 billion, a PE ratio of -22.28 and a beta of 0.65. Blueprint Medicines Co. has a fifty-two week low of $43.89 and a fifty-two week high of $110.93. The company has a debt-to-equity ratio of 1.60, a current ratio of 3.76 and a quick ratio of 3.66.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings results on Thursday, February 15th. The biotechnology company reported ($1.82) EPS for the quarter, topping analysts’ consensus estimates of ($2.04) by $0.22. Blueprint Medicines had a negative return on equity of 215.07% and a negative net margin of 102.15%. The company had revenue of $71.96 million during the quarter, compared to analysts’ expectations of $67.34 million. During the same quarter in the previous year, the firm earned ($2.65) EPS. Blueprint Medicines’s revenue was up 85.5% on a year-over-year basis. Equities analysts expect that Blueprint Medicines Co. will post -5.38 earnings per share for the current fiscal year.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.